MX376241B - Uso de anticuerpos anti-il-1a en el tratamiento de enfermedades vasculares y sus complicaciones. - Google Patents

Uso de anticuerpos anti-il-1a en el tratamiento de enfermedades vasculares y sus complicaciones.

Info

Publication number
MX376241B
MX376241B MX2015004286A MX2015004286A MX376241B MX 376241 B MX376241 B MX 376241B MX 2015004286 A MX2015004286 A MX 2015004286A MX 2015004286 A MX2015004286 A MX 2015004286A MX 376241 B MX376241 B MX 376241B
Authority
MX
Mexico
Prior art keywords
complications
vascular disease
treating vascular
chance
expected
Prior art date
Application number
MX2015004286A
Other languages
English (en)
Spanish (es)
Other versions
MX2015004286A (es
Inventor
John Simard
Original Assignee
Xbiotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xbiotech Inc filed Critical Xbiotech Inc
Publication of MX2015004286A publication Critical patent/MX2015004286A/es
Publication of MX376241B publication Critical patent/MX376241B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • C07K16/245IL-1
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MX2015004286A 2012-10-04 2013-10-01 Uso de anticuerpos anti-il-1a en el tratamiento de enfermedades vasculares y sus complicaciones. MX376241B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261709754P 2012-10-04 2012-10-04
PCT/US2013/062903 WO2014055544A1 (en) 2012-10-04 2013-10-01 Treating vascular disease and complications thereof

Publications (2)

Publication Number Publication Date
MX2015004286A MX2015004286A (es) 2015-08-06
MX376241B true MX376241B (es) 2025-03-06

Family

ID=50432830

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015004286A MX376241B (es) 2012-10-04 2013-10-01 Uso de anticuerpos anti-il-1a en el tratamiento de enfermedades vasculares y sus complicaciones.

Country Status (12)

Country Link
US (3) US20140099321A1 (enExample)
EP (3) EP4628162A3 (enExample)
JP (1) JP6460993B2 (enExample)
KR (2) KR102296017B1 (enExample)
CN (2) CN104684929A (enExample)
AU (1) AU2013327501B2 (enExample)
CA (1) CA2886747C (enExample)
HK (1) HK1211960A1 (enExample)
IL (1) IL237765B (enExample)
MX (1) MX376241B (enExample)
RU (1) RU2671955C2 (enExample)
WO (1) WO2014055544A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6324720B2 (ja) 2010-06-18 2018-05-16 エックスバイオテク, インコーポレイテッドXbiotech, Inc. 関節炎治療
KR102748255B1 (ko) 2010-08-23 2024-12-31 엑스바이오테크 인코포레이티드 종양성 질병들에 대한 치료
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
JP6204915B2 (ja) 2011-09-23 2017-09-27 エックスバイオテク, インコーポレイテッドXbiotech, Inc. 悪液質治療
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
KR20190117579A (ko) 2017-02-16 2019-10-16 엑스바이오테크, 인크. 화농성 한선염의 치료
CN113874034A (zh) * 2019-05-03 2021-12-31 苏黎世大学 脑缺血再灌注损伤的治疗
KR102652849B1 (ko) 2022-03-14 2024-04-01 한국화학연구원 극성 아라미드 나노섬유로 제조한 하이드로겔

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
RU2235541C2 (ru) * 1994-10-04 2004-09-10 Эмори Юниверсити Лечение атеросклероза и других сердечно-сосудистых и воспалительных заболеваний
JP2003500069A (ja) * 1999-05-24 2003-01-07 インタールーキン ジェネティックス インク 再狭窄の診断及び治療薬
EP1471931A4 (en) * 2001-08-24 2006-06-14 Maine Medical Ct Res Inst NON-TRADITIONAL EXPORT OF COPPER-DEPENDENT PRO-INFLAMMATORY CYTOKINES AND METHODS, COMPOSITIONS, AND KITS THEREOF
WO2004100987A2 (en) * 2003-05-06 2004-11-25 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat neointimal hyperplasia
CN105467136B (zh) * 2008-05-30 2018-02-16 埃克斯生物科技公司 白细胞介素‑1α抗体及使用方法
CN107243077A (zh) * 2009-05-29 2017-10-13 爱克索马美国有限责任公司 IL‑1β抗体及其结合片段的心血管相关用途
JP5812669B2 (ja) 2011-04-27 2015-11-17 キヤノン株式会社 画像処理装置および画像処理方法およびコンピュータプログラム。

Also Published As

Publication number Publication date
WO2014055544A1 (en) 2014-04-10
HK1211960A1 (en) 2016-06-03
KR20210108496A (ko) 2021-09-02
EP3524621A1 (en) 2019-08-14
AU2013327501A1 (en) 2015-04-02
IL237765B (en) 2019-06-30
RU2671955C2 (ru) 2018-11-08
KR102296017B1 (ko) 2021-09-01
IL237765A0 (en) 2015-05-31
CA2886747C (en) 2023-12-05
CN104684929A (zh) 2015-06-03
AU2013327501B2 (en) 2018-08-09
US20180057585A1 (en) 2018-03-01
US20140099321A1 (en) 2014-04-10
RU2015110635A (ru) 2016-11-27
MX2015004286A (es) 2015-08-06
JP6460993B2 (ja) 2019-01-30
JP2015531397A (ja) 2015-11-02
EP4628162A2 (en) 2025-10-08
CN113018431A (zh) 2021-06-25
KR20150063076A (ko) 2015-06-08
EP4628162A3 (en) 2025-12-03
US20210403548A1 (en) 2021-12-30
CA2886747A1 (en) 2014-04-10
EP2904010A1 (en) 2015-08-12
EP2904010A4 (en) 2016-06-01
KR102429919B1 (ko) 2022-08-05

Similar Documents

Publication Publication Date Title
MX376241B (es) Uso de anticuerpos anti-il-1a en el tratamiento de enfermedades vasculares y sus complicaciones.
EP4349343A3 (en) Expression of mirnas in placental tissue
NZ595331A (en) Ex-vivo treatment of immunological disorders with pkc-theta inhibitors
NZ602219A (en) Methods and compositions for treating degos’ disease
PH12013501790B1 (en) Use of dpp iv inhibitors
JOP20140344B1 (ar) تركيبات وطرق لتقليل المضاعفات السلبية العظمي للقلب والاوعية الدموية
MX2011007397A (es) Inhibidores de dpp-iv para el tratamiento de la diabetes en pacientes pediatricos.
ZA201700196B (en) Methods for treating high cardiovascular risk patients with hypercholesterolemia
AR097178A1 (es) Diagnóstico y terapias anticáncer que comprenden células madre cancerosas
WO2012037519A3 (en) Acceleration of wound healing by growth hormone releasing hormone and its agonists
NZ702169A (en) The use of heat shock protein 90 (hsp90) modulators for the treatment of metabolic syndrome
MX2010006650A (es) Materiales y metodos para el tratamiento de proliferacion vascular ocular patologica.
JP2015531397A5 (enExample)
EP4279128A3 (en) Novel antibody binding to tfpi and composition comprising the same
PH12014500967A1 (en) A medicament for treating anterior eye disease comprising rebamipide and a tear-retaining agent
MX2013000986A (es) Sirna dirigido al vegfa y metodos de tratamiento in vivo.
GEP201706716B (en) Optimised subcutaneous therapeutic agents
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.
MX354981B (es) Medicamento para tratamiento terapeutico y/o mejoramiento de sepsis.
WO2012106497A3 (en) Selection and treatment of subjects
WO2013078376A3 (en) Isoxazole treatments for diabetes
HK1213921A1 (zh) 用於減少在植入支架後的糖尿病患者的主要不良心血管事件(mace)的雙重可變結構域(dvd)免疫球蛋白
Shen et al. Inguinal hernia repair with acellular tissue matrix patch for pediatric patients aged 6 to 18 years
Liu et al. Preventive effects of modified chitosan medical anti-adhesion membrane on postoperative intra-abdominal adhesion
张承磊 The treatment strategy of special distal landing zones in endovascular repair of abdominal aortic aneurysm

Legal Events

Date Code Title Description
FG Grant or registration
PD Change of proprietorship

Owner name: JANSSEN BIOTECH, INC.